- Home
- CELC vs KODK Comparison
CELC vs KODK Comparison
Compare CELC & KODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- KODK
- Stock Information
- Founded
- CELC 2011
- KODK 1880
- Country
- CELC United States
- KODK United States
- Employees
- CELC N/A
- KODK N/A
- Industry
- CELC Medical Specialities
- KODK Business Services
- Sector
- CELC Health Care
- KODK Consumer Discretionary
- Exchange
- CELC Nasdaq
- KODK Nasdaq
- Market Cap
- CELC 440.0M
- KODK 476.6M
- IPO Year
- CELC 2017
- KODK N/A
- Fundamental
- Price
- CELC $57.43
- KODK $6.00
- Analyst Decision
- CELC Strong Buy
- KODK
- Analyst Count
- CELC 5
- KODK 0
- Target Price
- CELC $53.60
- KODK N/A
- AVG Volume (30 Days)
- CELC 906.9K
- KODK 1.2M
- Earning Date
- CELC 08-14-2025
- KODK 11-11-2025
- Dividend Yield
- CELC N/A
- KODK N/A
- EPS Growth
- CELC N/A
- KODK N/A
- EPS
- CELC N/A
- KODK N/A
- Revenue
- CELC N/A
- KODK $1,037,000,000.00
- Revenue This Year
- CELC N/A
- KODK N/A
- Revenue Next Year
- CELC N/A
- KODK N/A
- P/E Ratio
- CELC N/A
- KODK N/A
- Revenue Growth
- CELC N/A
- KODK N/A
- 52 Week Low
- CELC $7.58
- KODK $4.26
- 52 Week High
- CELC $63.06
- KODK $8.24
- Technical
- Relative Strength Index (RSI)
- CELC 64.38
- KODK 49.71
- Support Level
- CELC $50.44
- KODK $5.73
- Resistance Level
- CELC $63.06
- KODK $5.94
- Average True Range (ATR)
- CELC 3.17
- KODK 0.20
- MACD
- CELC -0.47
- KODK 0.03
- Stochastic Oscillator
- CELC 60.71
- KODK 62.79
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About KODK Eastman Kodak Company Common New
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.